Top Tweets for #cm274
Sophisticated discussion by @Clara__Steiner, who offered great context on #DISCUS (@drenriquegrande), #CM274 (@MattGalsky) & neoadjuvant #GDF15 (@A@AndreaNecchi), drawing not just from #bladdercancer but other diseases. Excellent session - data from #CM274 a great primer for discussions I am sure we will have after @tompowles1 presents #IMvigor011. #ESMO25
Terrific talk from @mar_nataliya @UCIrvine who started her #MOASCAnnualMeeting25 update by highlighting work from @neerajaiims @huntsmancancer on #TALAPRO2 followed by #bladdercancer highlights on #CM274 from @MattMilowsky @UNC_Lineberger & #NIAGARA from @MattGalsky @TischCancer. A wonderful, up-to-date presentation with findings from @ASCO #GU25. Please follow @MOASC_Office for impt #oncology updates!
Fantastic discussant session from @ERPlimackMD this morning at #GU25
🔍 Role of peri-op IO in MIBC: #CM274 & #NIAGRA
🧬 Biomarker need to optimise stratification and minimise risk of over-treatment
➡️ Emerging risk adapted integrated biomarker driven studies (MODERN)
Excellent discussion by @ERPlimackMD on #CM274 which continues to show OS benefit with caveats:
➡️how can we avoid over treatment -> use of biomarkers - ctDNA, PDL1?
➡️only 50% got SOC NAC
➡️pts wouldn’t have received EV/P upon progression
➡️use of subQ nivo in future?
#GU25
🗣️Bladder Cancer Oral Abstracts #GU25
Dr @ERPlimackMD discussing Abs658 & Abs659: #CM274 #NIAGARA
#CM274 Can ctDNA and PDL1 improve patient selection? #MODERN
#NIAGARA Can we ascertain contribution of component parts for NeoAdj vs Adjuvant PD1 therapy?
👥 @DrRosenbergMSK @tompowles1 @PGrivasMDPhD @shilpaonc @tonight @Uromigos @urotoday @bergsa83 @BradMcG04 @CharleneMantia @bickythapa02 @BrendanGuercio @BladderCancerUS @ASCO @OncoAlert @OncBrothers @OncLive
🗣️Bladder Cancer Oral Abstracts #GU25
Dr @MattMilowsky presenting Abs658 Adjuvant NIVO for MIBC: efficacy and OS #CM274
N = 709
560 (79%) MIBC (NIVO = 279; PBO = 281);
284 (51%) MIBC w/ prior NAC
Median FU 36.1mo
♦️NIVO
♦️PLACEBO
ITT
✅ DFS: NIVO 25.6mo vs P 8.5mo (0.63; 0.51–0.78)
✅ OS: NIVO NR vs P 39.9mo (0.70; 0.55–0.90)
PDL1+
✅ OS: NIVO NR vs PBO 37.6mo (0.48; 0.29–0.77)
With prior NAC
✅ DFS: NIVO 19.6mo vs P 8.3m (0.58; 0.43–0.79)
✅ OS: NIVO 55.2 vs P 40.2mo (0.74; 0.53–1.03)
No Prior NAC
✅ DFS: NIVO 25.9mo vs P 13.7mo (0.69; 0.50–0.94)
✅ OS: NIVO NR vs PBO 37.7mo (0.67; 0.47–0.95)
🩺Clinical implications:
- Adjuvant NIVO is SOC for MIBC based on DFS and OS benefit across subgroups
❓Ongoing efforts leveraging ctDNA and NIVO/RELA
#MODERN @ALLIANCE_org @bergsa83 @MattGalsky https://t.co/9WYdfXtlER
👥 @DrRosenbergMSK @tompowles1 @PGrivasMDPhD @shilpaonc @ERPlimackMD @tonight @Uromigos @urotoday @BradMcG04 @CharleneMantia @bickythapa02 @BrendanGuercio @BladderCancerUS @ASCO @OncoAlert @OncBrothers @OncLive @CParkMD
Updates on #CM274 by @MattGalsky adjuvant nivo vs pcb x1yr in MIBC & commentary by Dr. Heijden #GU23:
🌀DFS 22.0mo vs 10.9mo (HR 0.71)
🌀PDL1+: 52.6mo vs 8.4mo (HR 0.52)
🌀Subgroup w no NAC, no benefit
🌀Primarily white men ECOG 0-1
🌀Await OS data
🌀Other adjuvant IO trials (-)
#GU23 Phenomenal discussion of #KN057 and #CM274 to conclude Oral Abstract Session B
Awaiting OS results from #CM274
@NKI_nl #VanDerHeijden
@OncoAlert
Ahead of the HOT discussion b/w @tompowles1 @MattGalsky tomorrow on adjuvant IO #CM274 and IMVigor010in MIUC #BladderCancer session #UromigosLive @Uromigos, we NEED your votes to this poll please! 👇👇👇🙏🙏
@apolo_andrea 🕊
@brian_rini @montypal @neerajaiims @DrRosenbergMSK
The #UromigosLive Poll Q1: @US_FDA approved adjuvant Nivo for all high risk UC pts but @EMA_News approved Nivo only for pts with PD-L1 + tumors. In IMVigor010 trial, ctDNA +pts had improved DFS&OS with atezo. Based on this info, in MIBC, adjuvant Nivo should be used in
Great GU debate by @MattGalsky & @shilpaonc:
❓adjuvant Nivolumab in pT3N1 UC w extensive squamous features, cisplatin ineligible (no NAC)
❗️These patients were excluded from #CM274 but molecular subtype may suggest response to IO. Perhaps #AMBASSADOR will help answer this.
Great discussion w @IyerGopa #ArleneSiefkerRadtkeMD #SethLernerMD re: #biomarkers & #bladdercancer. Broad support for #PROOF302 - even in face of exciting data from #CM274, so critical to keep this & the "tie-breaker" @ALLIANCE_org #AMBASSADOR in mind!
Hoping you will join us tonight from 5:30-7pm PT to discuss the latest & greatest from @ASCO #GU21 w @TiansterZhang @PGrivasMDPhD & @YungLyou - should be a lot of fun! We will cover #CLEAR, #9ER,
@SWOG 1500, #EV301, #CM274 & more! https://t.co/SSiFDgaFwc
Excited to share the results of @SWOG 1500, which we are presenting at @ASCO #GU21 & reporting in @TheLancet today. 1st, THANK YOU to patients & families. 2nd, hats off to a tremendous group of investigators. This was a team effort! Wanted to share how it all began: (1/13)
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers